Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 104.41M P/E - EPS this Y 72.70% Ern Qtrly Grth -
Income -37.4M Forward P/E -2.13 EPS next Y 3.30% 50D Avg Chg -1.00%
Sales 14.09M PEG -0.02 EPS past 5Y -61.15% 200D Avg Chg -70.00%
Dividend N/A Price/Book 5.79 EPS next 5Y 127.60% 52W High Chg -95.00%
Recommedations 2.00 Quick Ratio 2.90 Shares Outstanding 146.38M 52W Low Chg 26.00%
Insider Own 14.10% ROA -64.36% Shares Float 117.87M Beta -0.48
Inst Own 42.53% ROE -126.72% Shares Shorted/Prior 12.52M/13.04M Price 1.17
Gross Margin 33.41% Profit Margin -265.42% Avg. Volume 1,492,074 Target Price 3.40
Oper. Margin -279.44% Earnings Date Dec 5 Volume 807,211 Change -2.50%
About Veru Inc.

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Veru Inc. News
12/16/24 Veru Inc. (VERU) Reports Q4 Loss, Tops Revenue Estimates
12/16/24 US Penny Stocks To Consider In December 2024
12/11/24 The past three years for Veru (NASDAQ:VERU) investors has not been profitable
11/26/24 Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders
11/05/24 Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
10/21/24 Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss
10/16/24 Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress
10/09/24 Veru Inc (VERU) Q3 2024 Earnings Call Highlights: Strategic Cost Management and Revenue Growth ...
09/11/24 Veru to Present at the 2024 Cantor Global Healthcare Conference
08/11/24 Earnings Beat: Veru Inc. (NASDAQ:VERU) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
08/10/24 Veru Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
08/08/24 Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates
08/08/24 Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results
08/01/24 Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024
07/29/24 Veru to Participate in the BTIG Virtual Biotechnology Conference
07/02/24 Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
07/02/24 Veru (NASDAQ:VERU) investors are sitting on a loss of 89% if they invested three years ago
06/24/24 Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions
06/18/24 Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
06/17/24 Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Shareholders
VERU Chatroom

User Image Braverabbit Posted - 9 hours ago

$VERU That Bearish ST dial isn't correct. Let's hit the Bullish button and have a Merry Christmas and Happy Holidays, Everyone!

User Image RemitTekram Posted - 12 hours ago

$VERU .

User Image NolAsrtormZ Posted - 18 hours ago

$VERU Mega Millions drawing tonight 1Billion $ jackpot

User Image NolAsrtormZ Posted - 20 hours ago

$VERU the handle of the cup is at $16.00 a share🎅🎅🎅

User Image NolAsrtormZ Posted - 20 hours ago

$VERU getting ready 2 make the other side of the cup🤑

User Image RemitTekram Posted - 23 hours ago

$VERU Dang it! I wish I bought the dip today. Oh yeah... I did. Hope this is the first half of a cup in the chart.

User Image PennyConnection1 Posted - 1 day ago

$VERU mother efer! So much for a Santa rally on this one for us

User Image mrkymrk Posted - 1 day ago

$VERU well, merry Christmas

User Image Woundntyouliketoknow Posted - 1 day ago

$VERU The medical breakthroughs to watch out for in 2025 “In addition, there has been much discussion of GLP-1 treatment causing undesired loss of muscle mass, in addition to the intended reduction of adipose tissue. Early in 2025, we should see data for ‘enobosarm’, which stimulates muscle-building hormones, which is being tested in combination with Wegovy to determine whether it may limit muscle loss.” https://inews.co.uk/news/health/medical-breakthroughs-2025-look-forward-3431785

User Image NVDAMillionaire Posted - 1 day ago

$VERU Veru Inc. (VERU): A Promising Biotech Tackling Unmet Needs in Weight Loss and Beyond https://beyondspx.com/article/veru-inc-veru-a-promising-biotech-tackling-unmet-needs-in-weight-loss-and-beyond

User Image Woundntyouliketoknow Posted - 1 day ago

$VERU I wonder how wall street will view data if they see a higher weight loss on the Enobosarm + GLP-1 arm at the 16 week mark vs GLP-1? Will there be some projections for the 28 week readout? What if there is no difference? What if weight loss is less on the Enobosarm + GLP-1 due to less muscle loss? Clearly there can be a lot of different outcomes that we might see.

User Image NolAsrtormZ Posted - 1 day ago

$VERU market closes early tomorrow, closed on Christmas.... Then there is only 27 trading days until end of January which data could come. This is extremely cheap data play especially with the hype around obesity/keep muscle market🤑🤑🤑 picture from xbi some1 posted

User Image Jperez18 Posted - 1 day ago

$VERU seeems like a good amount of new investors here, out of curiosity if yall don’t mind sharing how yall found out about the stock?

User Image RemitTekram Posted - 2 days ago

$VERU $0.64 seems to be the current battle line.

User Image RemitTekram Posted - 2 days ago

$VERU Dang it! I wish I took advantage of that dip this morning .... Oh ya ...... I did!!

User Image PennyConnection1 Posted - 2 days ago

$VERU

User Image Jimine Posted - 2 days ago

$VERU Raymond James - With 10-k, we updated model accordingly; F4Q results slight beat, and key Enobosarm Ph2b obesity data on track for Jan '25. Ph2b topline data for Enobosarm on lean body mass (LBM) preservation at 16 weeks in sarcopenic obese/ overweight patients taking a GLP-1 is still expected in January 2025, with more comprehensive data including secondary/functional endpoints to be provided at a subsequent medical meeting. Data from the GLP-1 roll-off/rescue portion of the study (extended additional 12 weeks) are still expected in C2Q25. Enobosarm remains leading muscle preservation asset with differentiated mechanism (oral SARM) and highly de-risked safety profile (large prior study database); scientific rationale is compelling into Ph2b readout. Additionally, co's working on a novel modified release formulation of Enobosarm that should help extend IP (Ph1 bioavailability trial initiating in 1H25). Adjusted est.'s slightly, TP remains $3; Outperform.

User Image NolAsrtormZ Posted - 2 days ago

$VERU Phase 3 data worth more then 98 million market cap🤑🤑🤑 how about 94 Billion

User Image NolAsrtormZ Posted - 2 days ago

$VERU Whats the float? (-) insiders , (-) tutes, (-) shorts??? Like 45million shares?

User Image NolAsrtormZ Posted - 2 days ago

$VERU If you start chipping away the share float *66million tutes aprx, * 7.8 million shares insiders aprx, 12.7 short shares aprx This share float is drying up👀👌

User Image NolAsrtormZ Posted - 2 days ago

$VERU According to Fintel, they r still adding. Now at 66milion shares owned by tutes. Over 45%

User Image NolAsrtormZ Posted - 2 days ago

$VERU This is a champ at following institutions buy ins

User Image NolAsrtormZ Posted - 2 days ago

$VERU ... few more months 2 see if institutions are continuing to add.

User Image NolAsrtormZ Posted - 2 days ago

$VERU surprisingly this shouldn't take to long. A year n half maybe, as popular as this path of muscle preservation has become

User Image NolAsrtormZ Posted - 2 days ago

$VERU 168 subjects took 3 to 4 months to enroll, so estimates for 4×/5× subjects would take a year or so

User Image NolAsrtormZ Posted - 2 days ago

$VERU pass phase 2 B, not sure phase 3 will be under the name Veru🤪🤑

User Image NolAsrtormZ Posted - 2 days ago

$VERU How far are other pharma companies in researching preservation of muscle mass while on diet drugs? Is Veru further along then most? Or about equal in these sudies?

User Image JxP2000 Posted - 3 days ago

$VERU any predictions in January when we might get data results??? Early/mid/late etc??

User Image AIIAAIIA_88 Posted - 4 days ago

$VERU I believe that it has a very cheap option for BP's weight loss drugs such as Wegovy, Ozempic, Munjaro, etc. to prevent muscle loss, by combining with Enobosarm oral intake. It could be BIG in 2025.

User Image RemitTekram Posted - 4 days ago

$VERU Averaged down for shorter term swing. 🤞

Analyst Ratings
B. Riley Securities Buy May 14, 24
HC Wainwright & Co. Buy May 13, 24
HC Wainwright & Co. Buy May 6, 24
Oppenheimer Outperform Apr 15, 24
Raymond James Outperform Mar 28, 24
HC Wainwright & Co. Buy Feb 8, 24
HC Wainwright & Co. Buy Sep 27, 23
Jefferies Hold Jun 7, 23
HC Wainwright & Co. Buy May 15, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Eisenberger Mario Director Director Aug 15 Option 1.67 100,000 167,000 100,000 08/17/22
Eisenberger Mario Director Director Aug 15 Sell 20.04 100,000 2,004,000 08/17/22